Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Frederiek NuytensFrederiek Nuytens, MD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France; Thibault Voron, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and Department of General and Digestive Surgery, Centre Hospitalier Universitaire Saint-Antoine, Sorbonne University, Paris, France; and Guillaume Piessen, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and University Lille, Centre National de la Recherche Scientifique, INSERM, Centre Hospitalier Universitaire Lille, UMR9020-U1277, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.ORCID 0000-0003-1194-0981
Thibault VoronFrederiek Nuytens, MD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France; Thibault Voron, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and Department of General and Digestive Surgery, Centre Hospitalier Universitaire Saint-Antoine, Sorbonne University, Paris, France; and Guillaume Piessen, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and University Lille, Centre National de la Recherche Scientifique, INSERM, Centre Hospitalier Universitaire Lille, UMR9020-U1277, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.ORCID 0000-0003-3236-5373
Guillaume PiessenFrederiek Nuytens, MD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France; Thibault Voron, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and Department of General and Digestive Surgery, Centre Hospitalier Universitaire Saint-Antoine, Sorbonne University, Paris, France; and Guillaume Piessen, MD, PhD, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, and University Lille, Centre National de la Recherche Scientifique, INSERM, Centre Hospitalier Universitaire Lille, UMR9020-U1277, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.ORCID 0000-0001-8243-8310
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE? · full record | OpenQuestion